In 2004, an asthma-drug venture called Actimis emerged from Bayer. Four years later, Boehringer Ingelheim agreed to acquire it through a staged deal potentially worth $515 million. The interesting number, though, may be the smaller one: Sanderling Ventures says its management approach saved Actimis approximately $15 million along the way.
- Back biomedical science before it becomes a complete business.
- Put experienced operators inside the company while keeping overhead lean.
- Build toward clinical evidence, then bring in the next owners or investors.
Actimis reached initial human trials on a single Series A financing, according to Sanderling. Peter McWilliams, the Sanderling investor responsible for the investment, also served as its CEO. There is something wonderfully literal about that arrangement. The person helping decide where the money went also had to help make the company work.
The $515 million deserves its own caution label. Boehringer’s announcement made the total conditional on successful development milestones. It was a possible deal value, not a cheque delivered on announcement day. In biotechnology, punctuation around a number can carry as much information as the number itself.
Estimated investment capital saved through Sanderling’s management strategy. A firm-reported comparison with typical venture-backed spending.
A scientist should not have to invent payroll
Robert McNeil founded Sanderling in 1979. Trained in molecular biology, biochemistry and genetics, he built an investment practice around young biomedical companies. His biography also records a fondness for restoring historic vessels. Both pursuits require patience with things that cannot be repaired by enthusiasm alone.
The firm says it has supported more than 90 biomedical companies. Its territory includes small molecules, biologics and vaccines, drug delivery, medical devices, diagnostics and digital health. Across those categories, it looks for technology with several possible product applications and entrepreneurs with strong technical backgrounds.
The recurring problem is organizational. A scientist can understand a target exquisitely and still need someone to recruit executives, assemble financial controls and navigate development decisions. Hiring an entire senior team immediately consumes cash before the experiment that matters has delivered an answer.
Sanderling’s answer is to share experienced people. Its principals can take CEO responsibilities and provide CFO-level support, generally during a venture’s first two years. The intended destination is a company with its own team. That makes the handover part of the design.
The investor takes an operating job
Consider the résumés. Fred Middleton joined Genentech’s original management team in 1978 and helped manage its 1980 IPO. He later joined Sanderling. Timothy Mills arrived after working in medical-device development and corporate leadership; his Sanderling roles have included chairman, CEO and management-team member.
McWilliams’s Actimis assignment makes the proposition tangible. An investor can supply judgment at a board meeting. An investor serving as CEO must turn judgment into a development programme, a budget and decisions other people can execute. That is the distinction founders should investigate when a fund advertises operational help.
Devices offer another illustration. Sanderling, Mayo Medical Ventures and entrepreneur Todd Berg founded Torax Medical to develop a treatment for reflux. Its LINX system used magnetic sphincter augmentation. Ethicon acquired Torax in 2017. Here, the financing organization helped assemble the venture around a defined clinical problem.
Pulsar Vascular followed a related route. Founded by Sanderling in 2005, it developed PulseRider, a saddle-shaped implant designed to help treat difficult brain aneurysms at branching arteries. Codman Neuro announced its acquisition in 2016. The shape is an apt detail: a very particular physical problem, addressed by a very particular piece of engineering.
“partners entrepreneurs with our active management resources”Timothy Mills, on Torax Medical, 2017
Someone has to finance the waiting
The business has two constituencies: entrepreneurs seeking capital and practical help, and investors supplying money to its funds. Those funds invest in biomedical businesses and pursue value through their growth and eventual liquidity. Founders are therefore investment partners; patients and hospitals use the resulting portfolio products.
In September 2013, BDC Venture Capital and the Fonds de solidarité FTQ announced a combined US$30 million commitment to a Canadian parallel fund alongside Sanderling VII. The agreement called for a permanent early-stage development facility in Montréal. Fund VII’s US$250 million figure was a target in that announcement.
This places Sanderling among specialist company builders, alongside alternatives such as ARCH Venture Partners and Third Rock Ventures. Building companies is a shared practice in this market. Sanderling’s distinctive pitch is its long biomedical history and the explicit provision of management inside fledgling ventures.
- 01Seed the science
- 02Share the operators
- 03Test the evidence
- 04Build the team
The experiment still gets a vote
Chimerix, a Sanderling portfolio company, supplies a useful corrective to the tidy success story. Its Phase 3 SUPPRESS trial failed its primary endpoint in 2015. The company subsequently reduced its workforce. Skilled managers and committed investors could not make that trial demonstrate the intended benefit.
Later came a different bet. Chimerix acquired Oncoceutics in 2021, adding the oncology candidate ONC201, subsequently named dordaviprone. The announced consideration was $78 million in cash and stock, plus contingent milestones and royalties. This was a new asset and development direction, rather than proof that the earlier clinical thesis had been right.
Jazz Pharmaceuticals completed its approximately $935 million cash acquisition of Chimerix in April 2025. That August, the FDA granted dordaviprone accelerated approval for a defined population with H3 K27M-mutant diffuse midline glioma after prior therapy. In February 2026, Jazz reported $48 million in Modeyso sales for 2025. These are portfolio-company milestones; the purchase price does not establish Sanderling’s proceeds.
The lesson a founder can borrow is practical: hire around the next decisive experiment, and specify what an investor’s help actually includes. Shared leadership needs clear authority and a planned transition. It offers less to a business with a complete executive team, or founders unwilling to share operating decisions. And its economics depend on conserving enough cash to reach evidence worth financing. Biology remains free to disagree.